propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid (4), the amidino group was converted to an oxadiazole ring, thiadiazole ring or substituted amidoxime group. These groups were expected to be metabolized to an amidino group in vivo. The compounds synthesized were evaluated for their potency to inhibit the ex vivo adenosine 5-diphosphate (ADP)-induced aggregation of guinea pig platelets. Among the compounds examined, the methoxycarbonyloxyamidine 8a exhibited the most potent ex vivo inhibitory activity with a fast onset and prolonged duration of action after oral administration.
The activation, adhesion and aggregation of platelets are important processes in the initiation of thrombus formation at sites showing high-grade stenosis, ruptured atheromatous plaque and endothelial damage within arteries. Recent studies on the biochemical mechanism of platelet activation indicate that the final obligatory step in aggregation is the crosslinking of the plasma protein fibrinogen and platelet membrane glycoprotein IIb/IIIa (GPIIb/IIIa) exposed on activated platelets. [1] [2] [3] [4] In the last decade, intensive effort has been devoted to the development of GPIIb/IIIa inhibitors to treat and prevent thrombotic disorders such as unstable angina and myocardial infarction. [5] [6] [7] [8] [9] [10] [11] [12] The clinical efficacy of the GPIIb/IIIa inhibitors has been demonstrated by positive results obtained with ReoPro 13, 14) (anti-GPIIb/IIIa c7E3 Fab antibody), Integrelin 15, 16) (cyclic peptide) and Aggrastat 17, 18) (non-peptide small molecule) used as intravenous treatments for acute thrombosis.
Orally active GPIIb/IIIa antagonists are required to expand the therapeutic utility of this class of agents and provide effective chronic treatment for patients with recurrent vascular events. Although a number of potent low molecular weight GPIIb/IIIa antagonists have been reported, their oral bioavailabilities are insufficient for practical use. The low bioavailability might be ascribed to the highly polar nature of these compounds due to the presence of a strong basic group and a carboxyl group. To improve the oral absorption of these compounds, a prodrug strategy has often been used. For example, Ro-48-3657 (1), 11) BIBU-104 (2) 19) and EMD-122347 (3) 20) exhibit sufficient oral bioavailabily, and 2 and 3 are currently being examined in clinical trials (Chart 1).
We recently reported the discovery of the potent GPIIb/ IIIa antagonist 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid (4) (Chart 1). 21) Following oral administration to guinea pigs, 4 was not absorbed sufficiently, and absolute bioavailability of 4 was not high enough for practical use. Our initial effort to obtain orally active ester prodrugs of 4 resulted in failure. In the case of the ester prodrugs of 4, due to unselective hydrolysis of the two ester groups, the prodrugs were not efficiently converted to the parent active form 4. 22, 23) We then turned our attention to masking the amidino group. While there are numerous reports on prodrugs of carboxylic acids, only a few prodrugs of aromatic amidines have been reported, for example, amidoximes, 11, 19) O-methylamidoximes, 24) alkoxycarbonylamidines 25, 26) and alkoxycarbonyloxyamidines. 26) In the clinical trials of the potent angiotensin II receptor antagonist TAK-536, 27, 28) the amidine derivative (M-1) in which the oxadiazolone ring in TAK-536 has been converted to an amidino group was detected as one of the metabolites (Chart 1). This suggested that an oxadiazolone ring might be able to serve as a masked amidino group and prompted us to investigate new in vivo amidino group equivalents. Since there are many pharmacologically important amidines with poor oral bioavailability, the development of masked amidino groups is of great significance. In this paper, we describe the synthesis and pharmacological profiles of prodrugs of 4 based on the creation of an oxadiazolone ring.
Chemistry
The target compounds 7a-l and 8a-d were synthesized as outlined in Chart 2 using 5 21) as the starting material. Hydrogenolysis of 5 in the presence of 10% Pd-C to remove the benzyloxycarbonyl (Z) group and subsequent condensation with appropriate benzoic acids (11, 14, 15, 19, 20, 21, 25, 30, 31, 35, 39 or 40) gave the intermediates 6a-l. Acid hydrolysis of the tert-butoxycarbonyl groups with trifluoroacetic acid (TFA) provided 7a-l. Acylation of the amidoxime carboxylate 6c followed by acid hydrolysis afforded 8a-d.
The benzoic acids used in the above condensation reactions were prepared from the 4-cyanobenzoates 9 and 22 . Treatment of 9 with hydroxylamine hydrochloride, followed by hydrolysis with 2 N NaOH, provided the amidoxime 11. 29) Cyclization of 10 with 1,1Ј-carbonyldiimidazole (CDI) and with 1,1Ј-thiocarbonyldiimidazole (TCDI) followed by hydrolysis afforded the oxadiazolone 14 The reaction of 36 with carbon disulfide and sulfur in the presence of sodium methoxide gave the thiadiazolethione 38, which was hydrolyzed to the carboxylic acid 40 (Chart 5).
Orally Active GPIIb/IIIa Antagonists: Synthesis and Biological Activities of Masked Amidines as Prodrugs of 2-[(3S)-4-[(2S)-2-(4-Amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid

Results and Discussion
First of all, to evaluate the potential usefulness of an oxadiazolone ring as a masked amidino group, metabolic conversion of the oxadiazolone 7a to the amidine 4 using guinea pig liver homogenate, small intestine homogenate and plasma was examined (Table 1) . After incubation of 7a in liver homogenate at 37°C for 1 h, the amount of 4 generated and that of 7a remaining were determined to be 15 and 22% based on the initial amount of 7a, respectively. After 1 h incubation in small intestine homogenate and plasma, no amount of 4 was detected, and the amount of 7a recovered was 73 and 58%, respectively. This suggested that the oxadi- a) Compond 7a was incubated in guinea pig liver homogenate, small intestine homogenate and plasma at 37°C for 1 h and then assayed by HPLC as described in the Experimental section. azolone ring could be metabolized to the amidino group by the reductive liver enzymes, 30) but not by esterases in the plasma or small intestine. The metabolic pathway was considered to be the cleavage of the N-O bond in the oxadiazolone ring, followed by elimination of carbon dioxide from the carbamic acid intermediate to lead to 4.
The results of the in vitro metabolic study encouraged us to evaluate 7a in vivo using guinea pigs. The ex vivo inhibitory effect of 7a on the adenosine 5Ј-diphosphate (ADP)-induced platelet aggregation in guinea pig platelet rich plasma (PRP) is shown in Fig. 1 . Oral administration of 7a at a dose of 0.3 mg/kg resulted in 91% inhibition at 8 h, and 38% inhibition was still observed at 24 h. On the contrary, 4 inhibited the platelet aggregation by 65 and 30% at 2 and 8 h, respectively. Since the in vitro antiplatelet effect of 7a was very weak even at a high concentration (Table 2) , 7a is considered to be metabolized to the biological active form 4, of which the plasma concentration could be estimated from the ex vivo potency of 7a after oral administration, in the body. While improved ex vivo potency and prolonged duration of action were observed with 7a as compared to 4, the onset of its action was slower than that of 4. This lag might be ascribed to sluggish conversion of 7a to 4, because the maximal concentration of 7a in the plasma 31) was observed 2 h after oral administration (data not shown).
To achieve a quick onset of action, some thioanalogs were examined because it was thought they might be more easily converted than 7a to 4. In fact, incubation of the thiadiazolone 7d in guinea pig liver homogenate at 37°C for 1 h generated more 4 than in the case of 7a (39% vs. 15%). The ex vivo inhibitory effects of the thioanologs 7b and 7d-f, whose in vitro antiplatelet effects were remarkably decreased (IC 50 : Ͼ4 mM, Table 2 ), are presented in Fig. 1 . Among these thioanalogs, the oxathiadiazolone 7f showed a potent in- hibitory effect comparable to that of 7a and a faster onset of action than 7a. On the contrary, the other thioanalogs, 7b, 7d and 7e, did not show enhanced ex vivo potency. Although the ex vivo activity of 4 was improved by conversion to 7a or 7f, more rapid onset of action was required. We then investigated some oxadiazoles, which might be metabolized to the amidino group through the same pathway as 7a. The ex vivo antiplatelet effect and the in vitro antiplatelet activities of the oxadiazoles 7g-7l are summarized in Fig. 2 and Table 2 . These compounds also had diminished in vitro antiplatelet activities ( Table 2 ). Conversion of the amidino group to an oxadiazole ring (7j) did not enhance the ex vivo activity as compared to that of 4. A dramatic decrease was observed with the 5-methyloxadiazole 7g and the 5-methoxyoxadiazole 7l, which possessed an electron donating group at the 5-position of the oxadiazole ring. On the contrary, introduction of an electron withdrawing group, such as a trifluoromethyl or a cyano group, increased the ex vivo antiplatelet effect. Oral administration of the 5-trifluoromethyloxadiazole 7i, and the 5-cyanooxadiazole 7k at a dose of 0.3 mg/kg, caused 71 and 56% inhibition at 4 h and 84 and 91% inhibition at 8 h, respectively. Introduction of the electron withdrawing group might facilitate the cleavage of the N-O bond to form the amidino group. The 5-phenyloxadiazole 7h was much less potent than 7j, providing only 9% of the maximal inhibition. While a phenyl group is a weak electron withdrawing group, the chemical stability of the phenyloxadiazole ring might prevent the reductive cleavage. The oxadiazoles 7i and 7k, bearing electron withdrawing groups at the 5-position, had ex vivo potency better than that of 4 but comparable to that of 7a and 7f.
We also evaluated the substituted amidoximes 7c and 8a-d, which are regarded as acyclic analogs of the corresponding oxadiazolone ring-bearing compounds (Fig. 3) . The replacement of the amidino group with an amidoxime group (7c) did not increase the ex vivo activity as compared to that of 4. We might ascribe the inefficacy of this modification to the presence of the hydroxyl group in 7c which reduced its lipophilicity. To increase the lipophilicity of 7c, the hydroxyl group was masked to lead to the amidoxime derivatives 8a-d. The methoxycarbonyloxyamidine 8a showed a pronounced inhibitory effect, fast onset and prolonged duration of action, which were superior to those of the other compounds prepared in this study. The inhibitory effect of 8a at 0.3 mg/kg p.o. was found to be 66, 82, 96 and 31% at 2, 4, 8 and 24 h, respectively. The metabolic pathway of 8a is considered to proceed via amidoxime 7c, 32) which is thought to be converted to amidine 4 by reductive enzymes in the liver. 11, 19) Rahmathullah and co-workers 26) reported the application of an alkoxycarbonyloxyamidino group as a masked amidino group to improve oral efficacy of an anti-Pneumocystis carinii agent, but that trial resulted in failure. Our study would be the first example showing the usefulness of an alkoxycarbonyloxyamidine group as a masked amidino group. The ethoxy-and the propoxycarbonyloxyamidines also displayed potent and long lasting ex vivo inhibitory activities, although these were inferior to that of 8a (data not shown). A faster onset of action and similar inhibitory activity were observed after oral administration of the methylthiocarbonyloxyamidine 8b as compared to 8a; however, its duration of action was shorter than that of 8a. The ethylcarbamyloxyamidine 8d also showed as potent inhibitory activity as 8a, but the onset of the action was slower than that of 8a. While the amidoxime derivatives 8a,b and 8d demonstrated good oral activity, enhanced ex vivo activity was not observed with the acetoxyamidine 8c.
The oral bioavailabilities of 4 and 8a, in terms of 4, in guinea pigs after a dose of 1 mg/kg i.v. (4) and 30 mg/kg p.o. (4) or 10 mg/kg p.o. (8a), were found to be 2.8 and 5.3%, respectively (Fig. 4) . The oral bioavailability as 4 was increased by about 2-fold with the methoxycarbonyloxyamidine 8a.
In conclusion, cyclic amidino groups, such as an oxadiazolone group, an oxathiadiazolone group, a 5-trifluoromethyloxadiazole group and a 5-cyanoloxadiazole group, as well as substituted amidoxime groups, such as a methoxycarbonyloxyamidino group and a methylthiocarbonyloxyamidino group, provided useful masked amidino groups to obtain orally active potent GPIIb/IIIa antagonists with a fast onset and prolonged duration of action. It is well known that there is no almighty prodrug promoiety for a carboxyl group. The best promoieties are dependent on the nature of the carboxylic acid. This is also true in the case of arylamidines, and a variety of promoieties should therefore be provided as candidates. The masked amidino groups discussed in this study could be additional examples to be considered. Although dramatic improvement of the oral bioavailability was not accomplished with the compounds examined in this study because of a remaining carboxyl group, these new masked amidino groups are expected to be useful for other arylamidines.
Experimental
Melting points were determined on a Yanagimoto micro melting point apparatus and are uncorrected. IR spectra were obtained on a Hitachi IR-215 spectrometer.
1 H-NMR spectra were recorded on a Varian Gemini 200 (200 MHz) spectrometer. Chemical shifts are given in d value (ppm) with tetramethylsilane (TMS) as the internal standard. The following abbreviations are used: sϭsinglet, dϭdoublet, tϭtriplet, ddϭdouble doublet, mϭ multiplet. Optical rotations were recorded on a JASCO DIP-370 digital polarimeter.
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoyl]amino]-propanoyl-3-oxopiperazinyl]acetate (6a)
A suspension of 5 (0.95 g, 1.59 mmol) and 10% Pd-C (0.25 g) in MeOH (50 ml) was hydrogenated under balloon pressure for 1 h at room temperature. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure to give amine. To a solution of this amine in N,N-dimethylformamide (DMF) (12 ml) were added 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoic acid 14 (0.36 g, 1.75 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (0.4 g, 2.09 mmol) at room temperature. After being stirred for 1 h, the mixture was diluted with ethyl acetate (EtOAc), washed with 5% aqueous KHSO 4 , dried over MgSO 4 , and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc-MeOH, 4 : 1) to give 6a (0.76 g, 73%) as a colorless amorphous powder. 1 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoyl]amino]-propanoyl-3-oxopiperazinyl]acetate (6b)
The title compound was prepared from 5 and 4-(5-thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoic acid 15 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 
Methyl 2-[(2S)-1-[(2S)-2-[[4-[Amino(hydroxyimino)methyl]benzoyl]-amino]-3-(4-methoxyphenyl)propanoyl]-4-[2-(tert-butoxy)-2-oxoethyl]-3-oxopiperazinyl]acetate (6c)
The title compound was prepared from 5 and 4-[amino(hydroxyimino)methyl]benzoic acid 11 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 1 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-thioxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)benzoyl]-amino]propanoyl-3-oxopiperazinyl]acetate (6e)
The title compound was prepared from 5 and 4-(5-thioxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)benzoic acid 40 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 1 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl]amino]propanoyl-3-oxopiperazinyl]acetate (6g)
The title compound was prepared from 5 and 4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoic acid 19 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 1 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-phenyl-1,2,4-oxadiazol-3-yl)benzoyl]amino]propanoyl-3-oxopiperazinyl]acetate (6h)
The title compound was prepared from 5 and 4-(5-phenyl-1,2,4-oxadiazol-3-yl)benzoic acid 21 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzoyl]amino]-propanoyl]-3-oxopiperazinyl]acetate (6i)
The title compound was prepared from 5 and 4-(5-trifluoromethyl-1,2,4-oxadiazol-3-yl)benzoic acid 20 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 1 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(1,2,4-oxadiazol-3-yl)benzoyl]amino]propanoyl]-3-oxopiperazinyl]acetate (6j)
The title compound was prepared from 5 and 4-(1,2,4-oxadiazol-3-yl)benzoic acid 30 according to the procedure described in the preparation of 6a as a colorless amorphous powder. 1 
Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-2-[[4-(5-cyano-1,2,4-oxadiazol-3-yl)benzoyl]amino]-3-(4-methoxyphenyl)propanoyl]-3-oxopiperazinyl]acetate (6k)
The title compound was prepared from 5 and 4-(5-cyano-1,2,4-oxadiazol-3-yl)benzoic acid 31 according to the procedure described in the preparation of 6a as colorless crystals, mp 185-187°C. 1 Methyl 2-[(2S)-4-[2-(tert-Butoxy)-2-oxoethyl]-1-[(2S)-2-[4-(5-methoxy-1,2,4-oxadiazol-3-yl) thioxo-4,5-dihydro-1,2,4-thiadiazol-3-yl) Following compound 7a-c and 7f-l were prepared according to the procedure described in the preparation of 7e. 
2-[(3S)-3-(2-Methoxy-2-oxoethyl)-4-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)benzoyl]amino]propanoyl]-2-oxopiperazinyl]acetic Acid (7d)
A suspension of 5 (1.8 g, 3.0 mmol) and 10% Pd-C (0.32 g) in MeOH (80 ml) was hydrogenated under balloon pressure for 1 h at room temperature. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure to give amine. Then, to a solution of this amine in DMF (18 ml) were added 4-(5-oxo-4,5-dihydro-1,2,4-thiadiazol-3-yl)benzoic acid 39 (0.74 g, 3.32 mmol) and EDC (0.76 g, 3.6 mmol) at room temperature. After being stirred for 1 h, the mixture was diluted with EtOAc, washed with 5% aqueous KHSO 4 , dried over MgSO 4 , and concentrated under reduced pressure to give crude 6d.
Then, a mixture of 6d, CH 2 Cl 2 (5.0 ml) and TFA (5.0 ml) was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure and the residue was recrystallized from EtOH to give 7d (0.87 g, 47%) as colorless crystals, mp 224-226°C. [ 
2-[(3S)-4-[(2S)-2-[[4-[Amino[[(methoxycarbonyl)oxy]imino]methyl]-benzoyl]amino]-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (8a)
To a mixture of 6c (3.50 g, 5.59 mmol), potassium carbonate (0.39 g, 2.80 mmol) and 1,4-dioxane (11.2 ml) was added dropwise methyl chloroformate (0.45 ml, 5.87 mmol) at room temperature. After being stirred for 1 h at room temperature, the mixture was poured into aqueous 5% KHSO 4 and extracted with EtOAc. The organic layer was dried over MgSO 4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc) to give ester (3.23 g, 85%) as a yellow amorphous powder. Then, a mixture of the ester, TFA (5.0 ml) and CH 2 Cl 2 (5.0 ml) was stirred for 1 h at room temperature. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (CHP-20, gradient elution: H 2 
2-[(3S)-4-[(2S)-2-[[4-[[(Acetyloxy)imino](amino)methyl]benzoyl]-amino]-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (8c)
The title compound was prepared from 6c and acetyl chloride according to the procedure described in the preparation of 8a as a colorless amorphous powder, [a ] D 20 ϩ13.1°(cϭ1.00, DMSO). 
2-[(3S)-4-[(2S)-2-[[4-[Amino[[[(ethylamino)carbonyl]oxy]imino]-methyl]benzoyl]amino]-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic Acid (8d)
The title compound was prepared from 6c and ethyl isocyanate according to the procedure described in the preparation of 8a as a colorless amorphous powder, 7 mmol) at room temperature and the mixture was stirred for 30 min at 110°C. After being cooled, solvent was removed by evaporation and then water was added to the residue. The mixture was adjusted to pH 2 with 3 N HCl, and the precipitate was collected and washed with water. Recrystallization from DMF-EtOAc gave 12 (3.1 g, 69%) as colorless crystals, mp 278-280°C. ene (98%, 3.35 g, 21. 6 mmol) at room temperature, and the mixture was stirred for 30 min at 80°C. After being cooled, the solvent was removed by evaporation and then water was added to the residue. The mixture was adjusted to pH 2 with 3 N HCl, and the precipitate was collected, washed with water, and dried to provide 13 (4.74 g, 97%) as colorless crystals, mp 202-203°C (dec. Thioxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) benzoic Acid (15) A suspension of 13 (4.74 g, 20 mmol), 2 N NaOH (30 ml) and MeOH (50 ml) was stirred for 16 h at room temperature, and the solvent was removed by evaporation. Water was added to the residue, and the mixturte was adjusted to pH 2 with 3 N HCl. The precipitate was collected, washed with water, and dried to give 15 (2.27 g, 51%) as colorless crystals, mp Ͼ300°C. To a mixture of 10 (1.94 g, 10 mmol), pyridine (1.04 ml, 13 mmol) and xylene (50 ml) was added benzoyl chloride (1.39 ml, 12 mmol), and the mixture was stirred for 1 h at 140°C. After being cooled, the mixture was diluted with EtOAc, washed with water, saturated aqueous NaHCO 3 and brine, dried over MgSO 4 , and concentrated under reduced pressure. The residue was recrystallized from hexane to provide 18 (2.54 g, 91%) as colorless crystals, mp 151-152°C. tert-Butyl 4-(5-Cyano-1,2,4-oxadiazol-3-yl)benzoate (29) To a mixture of 28 (0.58 g, 2.0 mmol), pyridine (0.4 g, 5.0 mmol) and 1,4-dioxane (8 ml) was added trifluoroacetic anhydride (0.34 ml, 2.4 mmol) at 0°C. After being stirred for 13 h at room temperature, the mixture was diluted with EtOAc, washed with water and brine, dried over MgSO 4 , and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-EtAOc, 2 : 1) to provide 29 (0.18 g, 33%) as colorless crystals (hexane), mp 102-104°C. 1 tert-Butyl 4-(5-Methoxy-1,2,4-oxadiazol-3-yl)benzoate (33) To a solution of 23 (2.36 g, 10 mmol) in 1,4-dioxane (25 ml) was added CDI (2.1 g, 13 mmol) at room temperature and the mixture was stirred for 30 min at 90°C. After being cooled, the mixture was concentrated under reduced pressure and the residue was partitioned between EtOAc (250 ml) and 5% aqueous KHSO 4 . Then, an excess solution of diazomethane in diethyl ether (15-20 mmol) was added dropwise to the organic layer at room temperature. After being kept standing for 18 h, the mixture was washed with water and brine, dried over MgSO 4 , and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-EtAOc, 2 : 1) to provide 33 (1.40 g, 51%) as colorless crystals (hexane-EtAOc 2 Cl 2 (50 ml) was added dropwise chlorocarbonylsulfenyl chloride (98%, 5.0 g, 37.4 mmol) at 0°C with vigorous stirring. After being stirred for 1 h at room temperature, the mixture was adjusted to pH 2 with conc. HCl and concentrated under reduced pressure. Water was added to the residue, and the precipitate was collected, washed with water, and dried to give 37 (3.8 g, 44%) as a yellow powder. Recrystallization from DMF-EtOAc gave 37 as colorless crystals, mp 263-265°C. 2 mmol) and MeOH (30 ml) was refluxed for 6 h. After being cooled, the mixture was concentrated under reduced pressure. Water was added to the residue and the mixture was adjusted to pH 2 with 3 N HCl. The precipitate was collected and recrystallized from MeOH to give 38 (3.3 g, 46%) as colorless needles, mp 201-203°C. 
4-(5-
